Opthea Limited's latest marketcap:
As of 04/30/2026, Opthea Limited's market capitalization has reached $529.55 M. According to our data, Opthea Limited is the 14936th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 529.55 M |
| Revenue (ttm) | -14,419.87 |
| Net Income (ttm) | 212.87 M |
| Shares Out | 1.23 B |
| EPS (ttm) | 0.17 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/29/2026 |
Opthea Limited's yearly market capitalization.
| Date | Market Cap(A$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 03/14/2025 | A$738.77 M | $483.23 M | -25.92% | 13791 |
| 12/31/2024 | A$997.31 M | $617.01 M | 163.98% | 11597 |
| 12/29/2023 | A$377.8 M | $257.2 M | -11.57% | 17356 |
| 12/30/2022 | A$427.23 M | $291.05 M | -6.26% | 15749 |
| 12/31/2021 | A$455.76 M | $330.65 M | -29.7% | 15895 |
| 12/31/2020 | A$648.32 M | $498.81 M | -19.17% | 11604 |
| 12/31/2019 | A$802.09 M | $562.67 M | 454.46% | 9451 |
| 12/31/2018 | A$144.66 M | $101.96 M | 2.48% | 17159 |
| 12/29/2017 | A$141.16 M | $110.22 M | 11.19% | 17475 |
| 12/30/2016 | A$126.95 M | $91.42 M | 111.32% | 16346 |
Company Profile
About Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. Operating in Australia and the United States, the company leverages its proprietary intellectual property to target conditions related to blood and lymphatic vessel growth.
Key Focus Areas
- VEGF-C & VEGF-D Inhibition: Specializes in therapies targeting vascular endothelial growth factors (VEGF-C, VEGF-D, and VEGF Receptor-3).
- Lead Product Candidate: Sozinibercept (OPT-302), currently in Phase 3 clinical trials, is designed to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
- Complementary Approach: Works alongside VEGF-A inhibitors to enhance therapeutic outcomes.
Corporate Background
Originally founded as Circadian Technologies Limited in 1984, the company rebranded to Opthea Limited in December 2015. Headquartered in South Yarra, Australia, Opthea serves the biotechnology and healthcare sectors with cutting-edge ophthalmic solutions.
Frequently Asked Questions
-
What is Opthea Limited's (ASX-OPT) current market cap?As of 04/30/2026, Opthea Limited (including the parent company, if applicable) has an estimated market capitalization of $529.55 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Opthea Limited (ASX-OPT) rank globally by market cap?Opthea Limited global market capitalization ranking is approximately 14936 as of 04/30/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.